The average demand for Actemra in intravenous format increased 279 percent from June 14-25 to Aug. 2-13, according to data Vizient released Aug. 26. Simultaneously, fill rates for hospitals’ orders of the drug decreased from 99 percent to 45 percent.
Actemra was used in just 4.5 percent of all COVID-19 cases, but these cases tended to be more severe, as evidenced by higher lengths of stay, rates of intensive care unit utilization and expected mortality. More than 40 percent of COVID-19 patients who received Actemra also receive invasive ventilation.
Hospitals are experiencing a shortage of the drug. On Aug. 16, Genentech said the shortage would last “at least the next several weeks.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
